Axel Sjöblad, Managing Director of BioGaia AB, summarizes the second quarter of 2017 and answers questions regarding:
- increase in sales and operating profit during this quarter compared to previous year
- strong gross margin during the first half year
- reasons behind the increase of operating expenses
- strong growth in the Americas
- start of subsidiary BioGaia Pharma
- possible acquisition opportunities of other companies, strains or products
Listen to telephone conference from 18 August 2017 about Interim report 1 January-30 June 2017
